Hikma signs transdermal patch supply agreement with SK Chemicals of South Korea

Published: 18-Feb-2014
Drug Delivery Pharmaceutical Dosage Forms

For the first approved generic Rivastigmine transdermal patch for dementia in Alzheimer\'s disease


Hikma Pharmaceuticals, a Jordanian multinational pharmaceutical group, has signed a licensing and supply agreement with SK Chemicals of South Korea for its reformulated generic Rivastigmine transdermal patch for the treatment of dementia in patients with Alzheimer’s disease.

Under the terms of the agreement, Hikma will have the exclusive licensing rights to register, distribute and market the patch (4.6mg/24hr, 9.5mg/24hr and 13.3mg/24hr) in 18 markets in the Middle East and North Africa (MENA).

Hikma has a strong local presence and regulatory expertise in MENA, with more than 1,600 sales and marketing reps across the region.

SK Chemicals’ product is the first generic version of the Rivastigmine transdermal patch to receive approval.

'This is an excellent product and will enhance our growing portfolio of central nervous system products,' commented Said Darwazah, CEO of Hikma.

'Bringing the first generic of this innovative product to the MENA region supports our strategy of increasing patients’ access to high quality, affordable medicines.'

Inseork Lee, CEO of SK Chemicals, added: 'I am very confident that we can achieve success with this product through a combination of SK Chemicals’ accumulated R&D ability and Hikma’s outstanding sales and marketing capabilities in MENA.'

  • Companies:
  • Hikma Pharmaceuticals
See more

You may also like

Regulatory

Status update on ANDA for generic Advair Diskus (VR315 [US])

Read more
Vectura Group, an industry leading inhalation CDMO, confirms the announcement made by its partner Hikma Pharmaceuticals

Trending Articles

  1. Sanofi invests €40m into biopharmaceutical manufacturing at its Lyon Gerland site The pharma giant has expanded its French monoclonal antibody production capabilities, while also dedicating €25m to the development of a second-gen polyclonal antibody
  2. Cleancube multi: Guardtech’s container facilities support NHS aseptic pharmacies Award-winning mobile cleanrooms offer fast, flexible solutions for facility upgrades
  3. Pharmaceutics International bolsters its prefilled syringe production capabilities The aseptic and oral dosage CDMO has invested USD $3.6m into advanced labelling, fill/finish and automated visual inspection technologies at its Hunt Valley site in Maryland, US
  4. Ardena's Oss nanomedicine facility gains full GMP approval from the Dutch Healthcare Authority The pharmaceutical manufacturing facility can produce advanced nanoparticle drug delivery systems, including lipid-based, polymeric and metal oxide nanoparticles
  5. Pfizer gains European Commission approval for haemophilia A and B drug, Hympavzi The subcutaneous therapeutic is the first and only anti-tissue factor pathway inhibitor approved for the treatment of haemophilia A or B, and is available in an auto-injector format

Upcoming event

CPhI India

26–28 November 2024 | Online Conference & Networking | Delhi, India See all

You may also like

Regulatory

Status update on ANDA for generic Advair Diskus (VR315 [US])

Vectura Group, an industry leading inhalation CDMO, confirms the announcement made by its partner Hikma Pharmaceuticals
Manufacturing

Hikma establishes distribution partnership with Melinta

The agreement covers distribution of an antibiotic effective against MRSA across the Middle East and North African region
Distribution

Hikma announces exclusive agreement with Sciecure Pharma for niche injectable antiviral medicine

Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world
Regulatory

Hikma launches Dalfampridine Extended-release tablets

Hikma Pharmaceuticals, formerly known as West-Ward Pharmaceuticals, has launched Dalfampridine Extended-release tablets, 10 mg, the generic therapeutic equivalent to Ampyra
Pharmaceutical

Hikma launches Clobazam oral suspension and Clobazam tablets

Hikma Pharmaceuticals has launched Clobazam oral suspension, 2.5 mg/mL, and Clobazam tablets, 10 and 20 mg, the generic equivalent to Onfi
Drug Delivery

Hikma announces agreement with Vectura to develop generic salmeterol for the US market

Hikma is a fast-growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products
Finance

Hikma to buy Boehringer Ingelheim's Roxane business for US$2.65bn in cash and stock

Will boost its presence in US generics market
Subscribe now